Resultado de búsqueda
22 de jul. de 2007 · Moser M, Frishman W: Results of therapy with carvedilol, a β-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 1998, 11:15S–22S. Article PubMed CAS Google Scholar Kanto JH: Current status of labetalol, the first alpha-and beta-blocking agent.
26 de may. de 2012 · Beta-blockers are widely prescribed for the treatment of a variety of cardiovascular pathologies. Compared to traditional beta-adrenergic antagonists, beta-blockers of the new generation exhibit ancillary properties such as vasodilation through different mechanisms. This translates into a more favorable hemodynamic profile. The relative affinities of beta-adrenoreceptor antagonists towards the ...
17 de ago. de 2023 · This allows the arteries to relax and open. Beta blockers. These medicines help the heart beat slower and with less force. Renin inhibitors. Renin is a substance made by the kidneys. It triggers a series of steps that increases blood pressure. Renin inhibitors slow how much of this substance is made.
23 de ago. de 2023 · Calcium channel blockers are medicines used to lower blood pressure. They stop calcium from entering the cells of the heart and arteries. Calcium causes the heart and arteries to squeeze more strongly. By blocking calcium, calcium channel blockers allow blood vessels to relax and open. Some calcium channel blockers also can slow the heart rate.
28 de dic. de 2021 · Treatment of heart failure follows the same treatment regimen regardless of the underlying cause (ie, ACE inhibitors, beta-adrenergic blockers). Intensive immunosuppressive therapy (eg, corticosteroids, azathioprine, cyclosporine, muromonab-CD3/OKT3) has been shown to have some benefit only in small-scale clinical studies in the treatment of giant cell myocarditis and has not been validated in ...
10 de abr. de 2024 · β-blockers are a diverse class of drugs, differentiated by varying (or absent) selectivity for blockade of β 1 - vs. β 2-adrenoceptors, intrinsic sympathomimetic activity at either or both of these receptors, the presence or absence of additional vasodilator mechanisms (actions of β 3-adrenoceptors that stimulate nitric oxide formation or blockade of α 1-adrenoceptors), and differences in ...
17 de may. de 2021 · This review summarizes the latest evidence for treatment of primary Raynaud's phenomenon (RP) using drugs with vasodilator effects excluding calcium channel blockers. Seven new studies were identified for this update. In total, 15 studies with 635 participants were included.
